Forest Services
Introduction: The Challenge of Antibiotic Resistance and Old Drugs
India accounts for 23% of global antibiotic consumption, yet over 50% of this usage is irrational or without prescription (WHO 2022; ICMR AMR Report 2023). Resistance rates for older antibiotics such as ampicillin exceed 70% among common pathogens (NCDC 2023). This escalating antimicrobial resistance (AMR) threatens to undermine decades of medical progress. Reviving the efficacy of old antibiotics through drug repurposing, adjuvant therapies, and regulatory reforms is essential to curb AMR and sustain public health outcomes.
UPSC Relevance
- GS2: Health - Antimicrobial resistance, National Action Plan on AMR
- GS3: Science and Technology - Drug development, Biotechnology
- Essay: Public health challenges and policy responses in India
Legal and Regulatory Framework Governing Antibiotics in India
The Drugs and Cosmetics Act, 1940 (amended 2020) regulates antibiotic approvals and quality control, ensuring safety and efficacy standards. The National Medical Commission Act, 2019 influences antibiotic prescription practices by regulating medical education and professional conduct. Environmental concerns related to antibiotic residues fall under the Environment Protection Act, 1986 (Section 3), indirectly impacting AMR containment. The Indian Penal Code Sections 269 and 270 criminalize negligent acts likely to spread infection, reinforcing public health safeguards. The National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017-2021 provides a comprehensive policy framework for antibiotic stewardship and containment strategies.
- Drugs and Cosmetics Act: Controls antibiotic manufacturing, import, and sale.
- National Medical Commission: Sets curriculum emphasizing rational antibiotic use.
- Environment Protection Act: Regulates disposal of pharmaceutical waste to prevent environmental AMR drivers.
- IPC Sections 269, 270: Penal provisions for negligent infection spread.
- NAP-AMR: Targets 30% reduction in antibiotic misuse by 2025.
Economic Dimensions of Reviving Old Antibiotics
India’s antibiotic market was valued at USD 3.5 billion in 2023, growing at a CAGR of 6.5% till 2028 (Frost & Sullivan 2023). However, unchecked AMR could cost the Indian economy up to USD 1.5 trillion by 2050 (World Bank 2017). Global investment in antibiotic R&D declined by 30% from 2010 to 2020 (WHO 2021), constraining new drug pipelines. Repurposing old antibiotics can reduce R&D costs by up to 60% compared to novel drug development (Nature Reviews Drug Discovery 2022). India’s dependence on imports for over 70% of antibiotic active pharmaceutical ingredients (APIs) (Pharmaceutical Export Promotion Council 2023) exposes supply chain vulnerabilities, underscoring the need for domestic innovation in repurposing and adjuvant therapies.
- Market size: USD 3.5 billion (2023) with steady growth.
- AMR economic burden: Potential USD 1.5 trillion loss by 2050.
- R&D investment decline globally: 30% reduction in a decade.
- Cost efficiency: Repurposing old antibiotics reduces R&D expenditure by 60%.
- Supply chain risk: >70% API imports for antibiotics.
Institutional Roles in Antibiotic Stewardship and Repurposing
The Indian Council of Medical Research (ICMR) leads AMR surveillance and research, providing critical data on resistance patterns. The Central Drugs Standard Control Organization (CDSCO) regulates antibiotic approvals and clinical trial oversight. The National Centre for Disease Control (NCDC) coordinates AMR containment programs at the national level. The Department of Biotechnology (DBT) funds research into drug repurposing and novel adjuvants. The Council of Scientific and Industrial Research (CSIR) develops innovative antibiotic adjuvants to restore efficacy. The World Health Organization (WHO) offers global guidelines on antibiotic use and stewardship frameworks.
- ICMR: AMR surveillance, resistance data generation.
- CDSCO: Drug approval and regulatory compliance.
- NCDC: National AMR containment coordination.
- DBT: Funding biotech research on repurposing.
- CSIR: Development of adjuvants enhancing old antibiotics.
- WHO: Global policy and technical guidance.
Scientific Strategies to Revive Old Antibiotics
Drug repurposing involves identifying new therapeutic uses for existing antibiotics, shortening development timelines and reducing costs. Adjuvant therapies combine old antibiotics with non-antibiotic compounds to inhibit resistance mechanisms, improving efficacy by up to 40% in clinical trials (Lancet Infectious Diseases 2023). Combination therapies can overcome bacterial resistance by targeting multiple pathways simultaneously. Rational use protocols and stewardship programs optimize dosing and duration to minimize resistance selection. Surveillance data guide targeted repurposing efforts against prevalent resistant strains.
- Drug repurposing: New indications for existing antibiotics.
- Adjuvant therapies: Resistance inhibitors combined with antibiotics.
- Combination therapies: Synergistic effects improve outcomes.
- Antibiotic stewardship: Rational prescription and use.
- Surveillance-guided targeting: Data-driven drug selection.
Comparative Analysis: India vs European Union Antibiotic Innovation
| Aspect | India | European Union (ND4BB Program) |
|---|---|---|
| Regulatory Adaptation | Fragmented, slower approval processes | Streamlined, incentivized repurposing and combinations |
| Public-Private Partnerships | Limited collaboration | Robust partnerships driving innovation |
| Antibiotic Approvals (2015-2022) | Minimal increase in effective approvals | 25% increase in effective antibiotic approvals |
| Stewardship Programs | Fragmented, weak at primary care level | Integrated, centralized stewardship models |
Challenges in India's Antibiotic Revival Efforts
India’s fragmented regulatory framework and lack of integrated stewardship programs at the primary healthcare level impede systematic repurposing and rational use of old antibiotics. Over-the-counter availability and irrational prescriptions exacerbate resistance. Limited investment in antibiotic R&D and dependence on imported APIs restrict innovation. Public awareness and healthcare provider training remain inadequate. These gaps contrast with centralized models in countries like Germany and Japan, which facilitate coordinated AMR responses.
- Regulatory fragmentation delays approvals.
- Weak stewardship at primary care level.
- High irrational antibiotic use.
- Low domestic R&D investment.
- Supply chain dependency on imports.
Way Forward: Concrete Measures to Reinstate Old Antibiotics
- Strengthen regulatory convergence by harmonizing CDSCO and state-level approvals.
- Expand and integrate antibiotic stewardship programs into primary healthcare settings.
- Increase funding for drug repurposing research via DBT and CSIR collaborations.
- Promote public-private partnerships modeled on EU’s ND4BB to incentivize innovation.
- Enhance surveillance systems through ICMR and NCDC to guide targeted antibiotic use.
- Implement strict enforcement of prescription-only antibiotic sales under the Drugs and Cosmetics Act.
- Develop domestic API manufacturing capacity to reduce supply chain vulnerabilities.
- Repurposing old antibiotics reduces R&D costs by approximately 60% compared to new drug development.
- Repurposed antibiotics always require full clinical trials equivalent to new drugs before approval.
- Adjuvant therapies can improve the efficacy of old antibiotics by targeting resistance mechanisms.
Which of the above statements is/are correct?
- The Drugs and Cosmetics Act, 1940 governs antibiotic approvals and quality control.
- The National Medical Commission Act, 2019 regulates antibiotic manufacturing standards.
- The Environment Protection Act, 1986 indirectly influences antibiotic residue management.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 - Health and Family Welfare, Public Health Policies
- Jharkhand Angle: High prevalence of infectious diseases and antibiotic misuse in rural Jharkhand increases AMR risk locally.
- Mains Pointer: Emphasize strengthening primary healthcare antibiotic stewardship and local surveillance to revive old antibiotics effectively.
What is drug repurposing in the context of antibiotics?
Drug repurposing involves identifying new therapeutic uses for existing antibiotics, reducing development time and costs compared to new drug discovery. It leverages known safety profiles to accelerate clinical application against resistant pathogens.
How does the National Action Plan on AMR (NAP-AMR) aim to reduce antibiotic misuse?
NAP-AMR 2017-2021 targets a 30% reduction in antibiotic misuse by promoting stewardship programs, rational prescription, surveillance, and public awareness campaigns across healthcare sectors.
Why is India’s dependence on imported APIs a concern for antibiotic efficacy?
India imports over 70% of antibiotic active pharmaceutical ingredients, creating supply chain vulnerabilities. Disruptions can limit access to quality antibiotics, hindering timely treatment and fostering resistance development.
What role does the Central Drugs Standard Control Organization (CDSCO) play in antibiotic regulation?
CDSCO is the national regulatory authority responsible for approving antibiotics, overseeing clinical trials, and ensuring compliance with safety and efficacy standards under the Drugs and Cosmetics Act.
How do adjuvant therapies enhance the effectiveness of old antibiotics?
Adjuvant therapies combine antibiotics with compounds that inhibit bacterial resistance mechanisms, such as efflux pumps or enzymes, thereby restoring or enhancing antibiotic efficacy against resistant strains.